Nucleic Acid Therapeutics CDMO Market Size, Share, Trends, Growth Outlook

Nucleic Acid Therapeutics CDMO Market is estimated to increase at a growth rate of 10.6% CAGR over the forecast period from 2024 to 2030.

The global Nucleic Acid Therapeutics CDMO Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Gene Therapy, RNA-based Therapies), By Service (Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services, Others), By Application (Oncology, Genetic Disorders, Infectious Diseases, Others), By End-user (Pharmaceutical Companies, Government & Academic Research Institutes, Biotech Companies).

An introduction to Nucleic Acid Therapeutics CDMO Market in 2024

Enabling the development and production of nucleic acid-based therapeutics, the Nucleic Acid Therapeutics CDMO market offers contract development and manufacturing services for RNA and DNA-based drugs, gene therapies, antisense oligonucleotides, and nucleic acid vaccines. Nucleic acid therapeutics CDMOs provide expertise in nucleic acid chemistry, formulation development, process optimization, and cGMP manufacturing, supporting biopharmaceutical companies in bringing nucleic acid-based drugs from preclinical development through clinical trials to commercialization. The market's growth is driven by the expanding pipeline of nucleic acid therapeutics, technological advancements in oligonucleotide synthesis and delivery, and increasing investment in nucleic acid drug development for a wide range of diseases and therapeutic applications.

Nucleic Acid Therapeutics CDMO market Trend: Growing Demand for Nucleic Acid Therapeutics

A significant trend in the nucleic acid therapeutics contract development and manufacturing organization (CDMO) market is the growing demand for nucleic acid therapeutics. With advancements in RNA-based and gene editing technologies, there is increasing interest in nucleic acid therapeutics as potential treatments for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. Nucleic acid therapeutics, such as messenger RNA (mRNA) vaccines, antisense oligonucleotides, small interfering RNA (siRNA), and gene editing therapies, offer novel approaches to modulate gene expression, target specific disease pathways, and provide personalized treatments for patients. The trend towards nucleic acid therapeutics drives market growth and stimulates demand for contract development and manufacturing services to support the development and production of these innovative therapies.

Nucleic Acid Therapeutics CDMO market Driver: Advancements in RNA-based and Gene Editing Technologies

The primary driver propelling the nucleic acid therapeutics contract development and manufacturing organization (CDMO) market is advancements in RNA-based and gene editing technologies. Recent breakthroughs in RNA interference (RNAi), mRNA-based vaccines, CRISPR-Cas gene editing, and other nucleic acid-based platforms have revolutionized the field of molecular medicine and opened new avenues for therapeutic intervention. These technologies offer precise targeting of disease-causing genes, modulation of gene expression, and correction of genetic mutations, presenting promising opportunities for the development of highly specific and effective therapeutics. As pharmaceutical and biotechnology companies increasingly explore nucleic acid-based approaches in drug discovery and development pipelines, there is growing demand for CDMO partners with specialized expertise, infrastructure, and capabilities in nucleic acid synthesis, formulation, and manufacturing to support the scale-up and production of nucleic acid therapeutics.

Nucleic Acid Therapeutics CDMO market Opportunity: Expansion of Manufacturing Capacity and Expertise

An exciting opportunity in the nucleic acid therapeutics contract development and manufacturing organization (CDMO) market lies in the expansion of manufacturing capacity and expertise. As the demand for nucleic acid therapeutics continues to rise, there is a need for CDMOs to scale up their manufacturing capabilities, infrastructure, and expertise to meet growing client requirements and accommodate larger batch sizes for clinical and commercial production. Opportunities for expansion include the investment in state-of-the-art manufacturing facilities equipped with specialized equipment for nucleic acid synthesis, purification, and formulation, as well as the recruitment and training of skilled personnel with expertise in RNA-based and gene editing technologies. Additionally, there is potential for the development of innovative manufacturing processes, automation solutions, and quality control systems to improve efficiency, scalability, and cost-effectiveness in nucleic acid therapeutics manufacturing. By expanding manufacturing capacity and expertise, nucleic acid therapeutics CDMOs can capitalize on the growing market demand, strengthen their competitive position, and better serve the needs of clients developing cutting-edge nucleic acid-based therapies, ultimately advancing the field of precision medicine and improving patient outcomes.

Nucleic Acid Therapeutics CDMO Market Market Segmentation

By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Nucleic Acid Therapeutics CDMO Market Companies

Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific

Reasons to Buy the Nucleic Acid Therapeutics CDMO Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Nucleic Acid Therapeutics CDMO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Nucleic Acid Therapeutics CDMO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Nucleic Acid Therapeutics CDMO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Nucleic Acid Therapeutics CDMO Market Size Outlook, $ Million, 2021 to 2030
3.2 Nucleic Acid Therapeutics CDMO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Nucleic Acid Therapeutics CDMO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Nucleic Acid Therapeutics CDMO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Nucleic Acid Therapeutics CDMO Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Nucleic Acid Therapeutics CDMO Industry
4.2 Key Market Trends in Nucleic Acid Therapeutics CDMO Industry
4.3 Potential Opportunities in Nucleic Acid Therapeutics CDMO Industry
4.4 Key Challenges in Nucleic Acid Therapeutics CDMO Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Nucleic Acid Therapeutics CDMO Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Nucleic Acid Therapeutics CDMO Market Outlook by Segments
7.1 Nucleic Acid Therapeutics CDMO Market Outlook by Segments, $ Million, 2021- 2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

8 North America Nucleic Acid Therapeutics CDMO Market Analysis and Outlook To 2030
8.1 Introduction to North America Nucleic Acid Therapeutics CDMO Markets in 2024
8.2 North America Nucleic Acid Therapeutics CDMO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Nucleic Acid Therapeutics CDMO Market size Outlook by Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

9 Europe Nucleic Acid Therapeutics CDMO Market Analysis and Outlook To 2030
9.1 Introduction to Europe Nucleic Acid Therapeutics CDMO Markets in 2024
9.2 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

10 Asia Pacific Nucleic Acid Therapeutics CDMO Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Nucleic Acid Therapeutics CDMO Markets in 2024
10.2 Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Nucleic Acid Therapeutics CDMO Market size Outlook by Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

11 South America Nucleic Acid Therapeutics CDMO Market Analysis and Outlook To 2030
11.1 Introduction to South America Nucleic Acid Therapeutics CDMO Markets in 2024
11.2 South America Nucleic Acid Therapeutics CDMO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Nucleic Acid Therapeutics CDMO Market size Outlook by Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

12 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Nucleic Acid Therapeutics CDMO Markets in 2024
12.2 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Nucleic Acid Therapeutics CDMO Market size Outlook by Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others